The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
A group of researchers have developed a brand new machine-learning mannequin that may exactly make prognosis predictions for sufferers with osteosarcoma, primarily based...
Professors, trainees, former colleagues, mentors, family and friends gathered to commemorate the legacy of Professor Jerry Pelletier, a scientist whose contributions...
